5 Potential Catalysts Could Spark (PKTX) To A Vertical Chart Move, Key Details Now

We have a lot to go over so let's dive in. 5 Potential Catalysts Could Spark (PKTX) To A Vertical Chart Move, Key Details Now March 22nd Dear Reader, We have a lot to go over so let's dive in. I recently had an interesting idea come across my desk and felt it necessary to bring it to your attention ASAP. Here's why... Multiple market opportunities. When 2025 rolls around, you could be looking at the following potential industry sizes: - Ophthalmology industry is $35.7Bn (1) - Dermatology industry is $183Bn (2) - Organ transplant industry is $51Bn (3) - Biomanufacturing industry is $218Bn (4) Choke on those for a second. LOL. Now, this company who has recently moved above several lines of potential support in recent days could be nearing a game-changing discover that could shape future medical industries forever. For Wednesday, March 23rd, there is one Biotech profile to have at the top of your watch-list: *ProtoKinetix, Incorporated (PKTX)* ProtoKinetix is a research and development company leading the way in cell survival solutions. AAGP, their patented anti-aging glycopeptide, is a revolutionary discovery that could shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. And right now, this profile has 5 potential catalysts to know ahead of Wednesday's opening bell. Check them out: No. 1 - Potential Support Levels Could Be Strengthening No. 2 - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing No. 3 - Partnering With NYSE Company To Accelerate Development Of AAGP No. 4 - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells No. 5 - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP But more on those in a second... ProtoKinetix Patented Molecule - Anti-Aging Glycopeptide (AAGP) AAGP key benefits AAGPs are small, stable molecules that display abilities in resolving challenges confronting medical researchers in regenerative medicine. Because of its molecular makeup, AAGP should function without side effects common in other treatments. Ophthalmology By regenerating retinal cells in humans and animals, AAGP has the potential to treat millions suffering from dry eyes and blindness. According to the Centers for Disease Control and Prevention, as many as 12 million Americans live with vision impairment. By regenerating retinal cells in humans, AAGP has the potential to treat people suffering from eye conditions. The company is researching three major ways that AAGP can help: retinal cell transplantation, ocular inflammation and veterinary treatments. Dermatology Compared to preventative skincare products that need to be applied before environmental exposure, AAGP can recover skin cells after the damage is done, as demonstrated in a laboratory setting. Chronic skin conditions can be both physically and mentally painful. In the United States, more than 85 million people are affected by skin conditions each year, according to the American Academy of Dermatology. AAGP can recover skin cells after the damage is done, as demonstrated in a laboratory setting. As a result, this molecule has the potential to make treatments for skin conditions more accessible and affordable. The company is researching two major ways that AAGP can help: inflammation protection as well as UV-radiation and burn recovery. Transplants During today’s transplants, organs can only survive around four hours. With AAGP, they hope to extend their viability to 24 hours. The impact: About 80 people receive transplants each day according to the Health Resources & Services Administration. Biomanufacturing In the realm of cell therapy and cancer immunotherapy, AAGP could be the link to essential advancements. The impact: Over 1 million people have been treated by cell therapies worldwide according to the Transparency Market Research. [Find sources and more details at the company website.]( And right now, PKTX has 5 potential catalysts to firmly know. Check them out: No. 1 PKTX Potential Catalyst - Potential Support Levels Could Be Strengthening Strong support levels could be growing for PKTX. Take a look: As of close on Monday, 3/21, PKTX saw [several lines of potential support]( strengthening. Those include its: - 5-Day Simple Moving Average (SMA) - 20-Day SMA - 5-Day Exponential Moving Average (EMA) - 13-Day EMA Additionally, PKTX's 5-Day EMA is trading above its 13-Day EMA in what can be considered a bullish manner. Watch these lines of potential support closely. ----- No. 2 PKTX Potential Catalyst - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing ProtoKinetix Announces Selection of AAGP Candidate Formulations for Treatment of Dry Eye Disease MARIETTA, Ohio, November 23, 2021--(BUSINESS WIRE)--ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation. The selection follows a seven-month formulation development program conducted by Catalent, in which the Active Pharmaceutical Ingredient (API) was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs. The efficacy testing will be conducted by EyeCRO of Oklahoma City. This study should be completed by mid to late January 2022. The resulting lead formulation will then undergo extensive Good Laboratory Practice (GLP) toxicology examination, to prepare a submission for the U.S. FDA for its approval to conduct clinical trials. [...] [Read the full article here.]( ----- No. 3 PKTX Potential Catalyst - Partnering With NYSE Company To Accelerate Development Of AAGP ProtoKinetix and IQVIA Partner to Support Development of AAGP Product in the Treatment of Ocular Conditions ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration. The ProtoKinetix-IQVIA collaboration will aim to accelerate the clinical development and regulatory progress of PKX-001. The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing for the above conditions. This initiative will also serve to optimize these clinical trials to determine safety in these new conditions, drawing from previous experience with PKX-001 in Type 1 diabetes and other conditions. [Read the full article here.]( ----- No. 4 PKTX Potential Catalyst - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP Treated Islet Cells in the Treatment of Type 1 Diabetes ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP (PKX-001) treated islet cells have resumed at the University of Alberta, Edmonton. All clinical trials were paused in 2020 due to CV-19 restrictions in the province. [...] [Read the full article here.]( ----- No. 5 PKTX Potential Catalyst - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP Enhanced Stem Cell Vision Restoration ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper describing and interpreting the results examining the benefit provided by AAGP to enable human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to restore vision in an experimental model of blindness due to retina degeneration. The paper has been published by the prestigious Journal of Tissue Engineering and Regenerative Medicine. The focus of this journal is therapeutic approaches which combine stem/progenitor cells with bioactive agents to restore, maintain, or improve tissue or organ function. [...] [Read the full article here.]( ----- PKTX Recap: 5 Potential Catalysts To Know Now No. 1 - Potential Support Levels Could Be Strengthening No. 2 - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing No. 3 - Partnering With NYSE Company To Accelerate Development Of AAGP No. 4 - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells No. 5 - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP ----- Coverage is officially initiated on PKTX. When you have a moment, do this: Get PKTX on your radar. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer [Source 1]( [Source 2]( [Source 3]( [Source 4]( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net